DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers is a phase 1/2, interventional study registered as NCT07707895 by Boehringer Ingelheim, with a registry enrolment figure of 60 participants, started 2026-09-29 and due to reach its primary completion in 2030-04-26. Interventions recorded: Obrixtamig; ZL-1310; Atezolizumab. Conditions listed: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology; Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology. Primary outcome: Part 1: The occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period; Part 2: The occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modification; Part 2: PFS rate at 6 months. Lung eligibility wording from the registry: "* Small cell lung carcinoma (SCLC)". Sites: Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain, United Kingdom, United States. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.